Efficacy Controls and Long-Term Follow-Up of Patients Treated With Rituximab for Relapsed or Refractory, Low-Grade or Follicular Non-Hodgkin’s Lymphoma

Publication
Article
OncologyONCOLOGY Vol 13 No 3
Volume 13
Issue 3

Rituximab (Rituxan), a chimeric monoclonal antibody (MoAb), binds with high affinity to the CD20 antigen found on malignant and normal B-cells, but not on other normal tissues. CD20 is an attractive target because of the accessibility and sensitivity of malignant B-cells to lysis via immune effector mechanisms. This MoAb mediates complement-dependent cell lysis and antibody-dependent cellular cytotoxicity. Also, it has been shown to sensitize chemoresistant human lymphoma cell lines and to induce apoptosis in vitro.

Rituximab (Rituxan), a chimeric monoclonal antibody (MoAb), binds with high affinity to the CD20 antigen found on malignant and normal B-cells, but not on other normal tissues. CD20 is an attractive target because of the accessibility and sensitivity of malignant B-cells to lysis via immune effector mechanisms. This MoAb mediates complement-dependent cell lysis and antibody-dependent cellular cytotoxicity. Also, it has been shown to sensitize chemoresistant human lymphoma cell lines and to induce apoptosis in vitro.

In a single-agent, pivotal trial in 166 patients with refractory, low-grade or follicular non-Hodgkin’s lymphoma (NHL) (International Working Formulation [IWF] types A, B, C, D) treated with rituximab at 375 mg/m² weekly for four infusions, the overall response rate (ORR) was 48% (6% complete and 42% partial responses). Responses (computed tomographic [CT] scans) were confirmed in a blinded audit by independent lymphoma experts (LEXCOR panel) using rigorous response criteria. Median time to progression for responders was 13.2 months, and median duration of response was 11.6 months.

Of 80 responders, 20 remain in ongoing remission at 19.3+ to 36.7+ months. The ORR did not vary significantly with the number of prior courses of chemotherapy: one, two, or three courses (P = .19) but decreased, as expected, with the number of relapses: one, two, or three (P = .04), ranging from 57% to 38%. Refractory patients with zero relapses (never responded, never relapsed) had an ORR of 29% (6/21).

This pivotal study had internal (patient as own control) and external (literature) controls. An intent-to-treat analysis (N = 166) showed a median duration of response to last chemotherapy of 12 months compared to 11.6 months following treatment with rituximab. The Kaplan-Meier graphs overlap and there is no significant difference in duration of response (P = .072; log rank test).

The overall response rate of 48% was compared to matched literature reports for fludarabine (Fludara) and cladribine (2-CdA [Leustatin]). The overall response rate to fludarabine across four studies (N = 138) was 41% (P = .23) and to 2-CdA in two studies (N = 61) 43% (P = .46).

CONCLUSION: A short (four infusions, 22 days) outpatient course of rituximab produces responses in patients with refractory low-grade or follicular NHL of equivalent duration to prior chemotherapy. The overall response rate obtained with rituximab compares favorably to that of other single agents. Furthermore, successful retreatment with rituximab has been reported and maintenance regimens are being studied. The MoAb has shown clinical activity in first and subsequent relapses, and in refractory and bulky disease. Front-line, combination, maintenance, and other studies are in progress. Initial studies in combination with chemotherapeutic and biological agents have shown promising results. Rituximab is now being evaluated in large randomized studies in patients with intermediate/high-grade NHL.

Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma
Rituximab: Phase II Retreatment Study in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma
Response Criteria for NHL: Importance of “Normal” Lymph Node Size and Correlations With Response
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
A Randomized Trial of Fludarabine, Mitoxantrone (FM) Versus Doxorubicin, Cyclophosphamide, Vindesine, Prednisone (CHEP) as First Line Treatment in Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma: A Multicenter Study by GOELAMS Group
Navelbine Increased Elderly Lung Cancer Patients’ Survival
Fludarabine Versus Conventional CVP Chemotherapy in Newly C Diagnosed Patients With Stages III and IV Low-Grade Malignant Non-Hodgkin’s Lymphoma: Preliminary Results From a Prospective, Randomized Phase III Clinical Trial in 381 Patients
Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma
Consensus Statement on Prevention and Early Diagnosis of Lung Cancer
In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL
Fludarabine and Cyclophosphamide: A Highly Active and Well-Tolerated Regimen for Patients With Previously Untreated Indolent Lymphomas
Campath-1H Monoclonal Antibody in Therapy for Advanced Low-Grade Non-Hodgkin’s Lymphomas: A Phase II Study
AIDS Drugs Effective Against Most Common HIV Strain
Rituximab Therapy in Previously Treated Waldenström’s Macroglobulinemia: Preliminary Evidence of Activity
Related Videos
Related Content